What it is
Dihexa is a small, chemically modified fragment of angiotensin IV, a breakdown product of the blood pressure hormone angiotensin. Its full chemical name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide. It was designed by the Harding and Wright research group, who had spent years studying angiotensin IV analogues as possible dementia treatments.
The problem with the earlier analogues was that they broke down quickly and could not cross the gut wall or the blood-brain barrier. Dihexa was the group's answer: a stabilised molecule that, in rats, works when swallowed and reaches the brain.
The single most important fact about dihexa is this: it has never been tested in a published human study. It sits in a cognitive peptide library because people buy it, not because the evidence has caught up.
How it works
The 2014 paper from the same group proposed the mechanism that is now generally cited:
- Dihexa binds tightly to hepatocyte growth factor (HGF), a growth factor that also acts in the brain.
- In the presence of small amounts of HGF, it increases activation (phosphorylation) of HGF's receptor, c-Met.
- In cultured hippocampal neurons it increased dendritic spines and new synapses, similar to HGF itself.
- Those effects disappeared when the researchers blocked HGF or silenced c-Met.
In other words, dihexa does not act as a hormone on its own. It amplifies an existing growth signal. That matters for the safety discussion below.
What the research found
Animal and cell studies
- McCoy and colleagues (2013) tested a series of stabilised angiotensin IV analogues in rats. Dihexa reversed memory deficits caused by the drug scopolamine and improved spatial learning in aged rats in the Morris water maze, a standard swimming-maze memory test. It also produced marked synapse formation in cell culture.
- Benoist and colleagues (2014) showed that the memory benefit of oral dihexa in rats was blocked by an HGF antagonist injected directly into the brain, which tied the effect to the HGF/c-Met system.
A 2021 review by the Alzheimer's Drug Discovery Foundation (ADDF) summarised the rat work as showing improved maze performance and close to a threefold increase in dendritic spines in hippocampal cultures. It also noted a half-life measured in days in rats, far longer than typical peptides.
Human studies
There are none. The ADDF review states plainly that no human studies have been published. Online claims that dihexa is "seven orders of magnitude" more potent than BDNF trace back to the developers; the ADDF pointed out that the two were never directly compared.
The closest human data: fosgonimeton
The same research line led to fosgonimeton (ATH-1017), a different molecule developed by Athira Pharma as a daily injection. It is the only drug from this family to reach large human trials. In September 2024 its phase 2/3 LIFT-AD trial in 312 people with mild to moderate Alzheimer's disease missed its primary endpoint over 26 weeks. That result does not tell us directly about dihexa, but it is a reminder that strong rat memory data in this pathway has not yet translated into patients.
Side effects reported in studies
No human side effect data exists. No long-term safety study has been done in animals either, according to the ADDF.
The main theoretical concern is cancer. HGF and c-Met form one of the best-known growth pathways in tumour biology, driving cell growth, invasion and spread in many cancer types. A compound built to boost that signal, taken daily for weeks, is exactly the kind of exposure that would need careful long-term toxicology before any human use. That work has not been published.
Dihexa vs other cognitive peptides
| Compound | Proposed mechanism | Best human evidence |
|---|---|---|
| Dihexa | HGF/c-Met amplification | None published |
| Semax | ACTH fragment, raises BDNF in rats | Russian clinical studies; registered in Russia |
| Selank | Tuftsin analogue, GABA modulation | Russian clinical studies; registered in Russia |
| Cerebrolysin | Porcine brain peptide mixture | Multiple RCTs and Cochrane reviews |
| Pinealon | Short bioregulator peptide | Very limited, one research group |
For a ranked overview see best peptides for brain function.
Status in the Philippines
No dihexa product is registered with FDA Philippines, and it is not an approved medicine in any country. It is not a controlled substance under RA 9165. Locally it circulates through research-chemical suppliers and a small biohacker crowd, far less commonly than Semax or Selank. Because it is sold as an unregulated research chemical, there is also no way for a buyer to confirm what a given product contains.
Storage
Dihexa is supplied as a dry powder. Keep it sealed, dry and away from light, ideally refrigerated. Philippine humidity is the bigger enemy for a powder than heat: keep a desiccant in the container and close it quickly after opening. See the beginner guide for handling basics.
